Elan Naprelan FTC subpoena
Executive Summary
Elan is responding to a December 2002 Federal Trade Commission subpoena regarding Naprelan, company discloses in Feb. 27 Securities & Exchange Commission filing. FTC opened an investigation in June 2001 to determine whether Elan had restricted generic availability of Naprelan (naproxen). Andrx brought suit against Elan and SkyePharma, claiming they had entered into an anti-competitive agreement for the pain agent (1"The Pink Sheet" April 9, 2001, p. 4). SkyePharma later waived its right to 180-day exclusivity, clearing the way for Andrx' generic (2"The Pink Sheet" July 15, 2002, p. 7)...